CSD201004: An Actual Use Study of P10 and P13 Nicotine Pouches Among U.S. Adult Smokers
Study Details
Study Description
Brief Summary
The purpose of this Actual Use Study (AUS) is to investigate how U.S. adult tobacco consumers 21-60 years of age) who are regular smokers (≥5 cigarettes/day) on at least 20 days out of the past 30 days will use P10 and P13 nicotine pouches (Study Investigational Product [IP]) over a 6-week Actual Use Period (AUP) in their real-life/naturalistic environment and in the context of typical consumer marketing materials. Subjects will self-report their ad libitum use of the Study IP as well as use of combustible cigarette (CC) and any other tobacco- or nicotine-containing product (TNP) on a daily basis using an electronic diary (eDiary). The study design is planned to address topics that FDA's Center for Tobacco Products (CTP) has identified as useful in evaluating new tobacco products.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
The AUS is a multi-site, open-label, 8-week, prospective observational study, conducted at multiple sites geographically dispersed within the U.S.
Adult smokers will be recruited, and candidate subjects who meet study inclusion criteria and none of the exclusion criteria will give verbal consent for further screening. Candidate subjects will be scheduled to attend an in-person Site Enrollment Visit (SEV).
At the SEV, site staff will confirm eligibility, including age verification with a government-issued photo identification. Candidate subjects will review product information and will be shown physical examples of the Study IP, but will not sample the products. Those who indicate an "intention to use" the Study IP will undergo a second consent process, will be enrolled in the study, and will install and be trained on an eDiary application on their personal smartphones or site provisioned devices.
During a 1-week Baseline Assessment Period (BAP, Week 0), enrolled subjects will record all CC and any other TNP use in the eDiary. At the end of the BAP, subjects will return to the study site for Site Visit 1 (SV1). At this visit, subjects will be able to select up to five different Study IPs for the first two weeks of the AUP from the Study IPs available.
During the subsequent 6-week observational AUP, subjects can choose to use the Study IP (or not). Subjects will be instructed to record all daily Study IP, TNP and CC use in the eDiary. They will return to the site every two weeks during the AUP for an in-person interview to answer questionnaires and for product accountability and resupply. As with SV1, at Site Visit 2 (SV2) and Site Visit 3 (SV3), subjects will be able to select up to five IP varieties (if desired) for use during the subsequent 2-week AUP. After Week 6 of the AUP, there will be a final site visit (SV4) and week-long Close Out Period (COP).
In addition to collecting information on daily ad libitum use of Study IP, TNP and CC use, the study will assess subjective measures (i.e., product assessment) for each Study IP, including product use behaviors and intent to use again (at close of study). Information on intention to quit CC will be collected at enrollment and at study conclusion. A passive surveillance mechanism will be used to collect information on adverse health experiences.
Study Design
Outcome Measures
Primary Outcome Measures
- Number and Proportion of Established Users [6 weeks]
Number and proportion of subjects who meet the definition of "established users" of the Study IP
- Number and Proportion of Established Users who reduce their CPD consumption [8 weeks]
Number and proportion of subjects among "established users" who reduce their CPD consumption by at least 50%
- Descriptive weekly average CPD consumption [8 weeks]
Descriptive weekly average CPD consumption per subject among all subjects who complete the study, including both established and non-established users of the Study IP
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Adult males or females, 21-60 years old, inclusive, verified with government-issued photo ID.
-
Must be a current smoker of factory-made filtered menthol and/or non-menthol cigarettes, has smoked at least 100 cigarettes in their lifetime, and typically smokes on at least 20 days out of the past 30 days.
-
Smokes on average ≥ 5 combustible cigarettes per day (CPD) on days when cigarettes are smoked. (There are no other requirements or exclusions regarding other TNP use. Dual and poly-users may enroll if they fulfill the cigarette use requirements.)
-
Must indicate "an intention to use" Study IP after a brief review of product information and product demonstration at the SEV. Subjects will not try the product at the SEV.
-
Available and interested in participating in an 8-week study about the Study IP.
-
Able and willing to comply with all study requirements, including questionnaires, the eDiary reporting procedures, and provide valid contact information.
-
Able to read, understand, and willing to sign Informed Consent Forms (ICFs) and complete questionnaires written in English.
-
Has not participated in any tobacco-, vapor-, or nicotine-related research within 3 months of screening.
-
Agrees that the IP received are for their own personal use and they will not share the product with others.
-
Agrees to restrict use of Study IP to only the investigational products (specified flavors, nicotine levels, and pouch sizes) supplied by the study Sponsor free of charge and labeled as "For Investigational Use Only" and to not obtain/use any other nicotine pouch products from other commercial sources.
Exclusion Criteria:
-
Self-reports as currently quitting or intending to quit within the next 3 months all tobacco or nicotine product use ("currently" is defined as within (≤) 30 days). Those who intend to quit CC only can be enrolled.
-
Must not be an ever-user of any nicotine pouches prior to screening.
-
Female subjects who are currently pregnant or breastfeeding or planning to become pregnant or start breastfeeding within the next 6 months based on self-report.
-
Female subjects who self-report they are not using adequate methods to prevent pregnancy.
-
Self-reports "poor" physical health (based on the five-category Population Assessment of Tobacco and Health (PATH) questionnaire): "In general, how would you rate your physical health?" (Response choices: Excellent, Very Good, Good, Fair, Poor).
-
Self-reports "poor" mental health (based on the five-category PATH questionnaire): "In general, how would you rate your mental health?" (Response choices: Excellent, Very Good, Good, Fair, Poor).
-
Employees of tobacco or vapor companies.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Schlesinger Phoenix | Phoenix | Arizona | United States | 85016 |
| 2 | Schlesinger Atlanta | Atlanta | Georgia | United States | 30328 |
| 3 | Schlesinger Chicago | Chicago | Illinois | United States | 60611 |
| 4 | Schlesinger Kansas City | Kansas City | Missouri | United States | 64114 |
| 5 | Schlesinger St. Louis | Saint Louis | Missouri | United States | 63131 |
| 6 | Schlesinger New Jersey | Iselin | New Jersey | United States | 08830 |
| 7 | Schlesinger Columbus | Columbus | Ohio | United States | 43235 |
| 8 | Schlesinger Philadelphia | Philadelphia | Pennsylvania | United States | 19103 |
| 9 | Schlesinger Dallas | Dallas | Texas | United States | 75254 |
| 10 | Schlesinger Houston | Houston | Texas | United States | 77027 |
Sponsors and Collaborators
- RAI Services Company
Investigators
- Study Director: Patrudu Makena, PhD, RAIS
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CSD201004